FGFR4 and chronic kidney disease: FGFR4 is a potential therapeutic target for reducing cardiovascular risk in patients with CKD as pharmacological blockage of this receptor in animal models showed attenuated LVH, while loss of function (FGFR4−/−) protected mice from developing LVH (64).